Exploring the intersection of genomic science and capitalism, this work examines how recent biotechnological advancements, such as CRISPR and genetically modified organisms, reshape the landscape of capital accumulation. It highlights the emergence of novel life-forms engineered in laboratories, which serve to enhance business operations across various sectors. The authors argue that these innovations reflect a broader socio-historical context of capitalist exploitation, as capital actively designs biological systems, fundamentally altering the global biosphere and impacting daily life.
